STOCK TITAN

Gilead Sciences director Kramer sells 10,376 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Gilead Sciences, Inc. (GILD) director Kelly A. Kramer exercised 10,376 non-qualified stock options on November 12, 2026, at an exercise price of $66.92 per share, acquiring 10,376 common shares. Kramer reported sales of 10,376 common shares that day in four transactions: 1,676 at $168.2255, 3,800 at $169.4423, 4,700 at $170.4941 and 200 at $171.44 per share. The transactions were made under a Rule 10b5-1 trading plan adopted August 13, 2026.

Insider Kramer Kelly A.
Role Director
Sold 10,376 shs ($1.76M)
Approx. gross sale proceeds $1.76M
Approx. exercise cost $694K
Approx. pre-tax spread $1.07M
Share of Position Sold 88.6%
Type Security Shares Price Value
Exercise Non-qualified Stock Option (Right to Buy) F1, F5 10,376 $0.00 $0.00
Exercise Common Stock F1 10,376 $66.92 $694K
Sale Common Stock F1, F2 1,676 $168.2255 $282K
Sale Common Stock F1, F3 3,800 $169.4423 $644K
Sale Common Stock F1, F4 4,700 $170.4941 $801K
Sale Common Stock F1 200 $171.44 $34K
Holdings After Transaction: Non-qualified Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 1,339 shares (Direct)
Holdings Before and After: Non-qualified Stock Option (Right to Buy), 10,376 to 0 options (Direct); Common Stock, 1,339 to 1,339 shares (Direct)
Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (5)
  1. F1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2026.
  2. F2. Sale prices for the transactions reported range from $167.95 to $168.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  3. F3. Sale prices for the transactions reported range from $169.04 to $169.90. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  4. F4. Sale prices for the transactions reported range from $170.08 to $171.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
  5. F5. 25% of the shares subject to the option vested on each three-month anniversary measured from May 10, 2017 such that 100% of the shares subject to the option were fully vested and exercisable on May 10, 2018.
Options exercised 10,376 options November 12, 2026
Exercise price $66.92 per share Options exercised November 12, 2026
Common shares acquired on exercise 10,376 shares November 12, 2026
Reported per-share price, 1,676-share sale $168.2255 per share November 12, 2026
Reported per-share price, 3,800-share sale $169.4423 per share November 12, 2026
Reported per-share price, 4,700-share sale $170.4941 per share November 12, 2026
Reported per-share price, 200-share sale $171.44 per share November 12, 2026
Option expiration date May 10, 2027 Non-qualified stock option
Rule 10b5-1 trading plan regulatory
"transactions reported were made pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-qualified Stock Option (Right to Buy) financial
"Non-qualified Stock Option (Right to Buy)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GILD shares did Kelly A. Kramer sell, and at what prices?

Kelly A. Kramer, a Gilead director, reported sales on November 12, 2026, of 1,676 shares at $168.2255 per share, 3,800 at $169.4423, 4,700 at $170.4941 and 200 at $171.44. The sales were made under a Rule 10b5-1 trading plan adopted August 13, 2026.

How many GILD stock options did Kelly A. Kramer exercise, and at what price?

Kramer exercised 10,376 non-qualified stock options at an exercise price of $66.92 per share on November 12, 2026, acquiring 10,376 common shares.

When did the GILD director's stock option expire?

The non-qualified stock option's expiration date was May 10, 2027. The related note states that it became fully vested and exercisable on May 10, 2018, after 25% vested on each three-month anniversary measured from May 10, 2017.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kramer Kelly A.

(Last)(First)(Middle)
333 LAKESIDE DRIVE

(Street)
FOSTER CITY CALIFORNIA 94404

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/12/2026M(1)10,376A$66.9211,715D
Common Stock11/12/2026S(1)1,676D$168.2255(2)10,039D
Common Stock11/12/2026S(1)3,800D$169.4423(3)6,239D
Common Stock11/12/2026S(1)4,700D$170.4941(4)1,539D
Common Stock11/12/2026S(1)200D$171.441,339D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-qualified Stock Option (Right to Buy)$66.9211/12/2026M(1)10,376 (5)05/10/2027Common Stock10,376$00D
Explanation of Responses:
1. The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan adopted on August 13, 2026.
2. Sale prices for the transactions reported range from $167.95 to $168.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
3. Sale prices for the transactions reported range from $169.04 to $169.90. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
4. Sale prices for the transactions reported range from $170.08 to $171.01. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
5. 25% of the shares subject to the option vested on each three-month anniversary measured from May 10, 2017 such that 100% of the shares subject to the option were fully vested and exercisable on May 10, 2018.
Remarks:
/s/ Amy Kim by Power of Attorney for Kelly A. Kramer11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading